Cargando…

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond

In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of monoclonal antibodies (mAbs) with the cytotoxic p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theocharopoulos, Charalampos, Lialios, Panagiotis-Petros, Samarkos, Michael, Gogas, Helen, Ziogas, Dimitrios C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538104/ https://www.ncbi.nlm.nih.gov/pubmed/34696218 http://dx.doi.org/10.3390/vaccines9101111

Ejemplares similares

An overview of antibody–drug conjugates in oncological practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
por: Ziogas, Dimitrios C., et al.
Publicado: (2021)

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
por: Anastasopoulou, Amalia, et al.
Publicado: (2019)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
por: Ziogas, Dimitrios C., et al.
Publicado: (2022)

Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al
por: Ziogas, Dimitrios C, et al.
Publicado: (2021)

Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature
por: Diamantopoulos, Panagiotis T, et al.
Publicado: (2023)

An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
por: Pal, Lal Bahadur, et al.
Publicado: (2023)

Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
por: Feld, Jonathan, et al.
Publicado: (2013)

Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review
por: Angelousi, Anna, et al.
Publicado: (2022)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2020)

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature
por: Anastasopoulou, Amalia, et al.
Publicado: (2021)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
por: MANTA, ASPASIA, et al.
Publicado: (2023)

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
por: Mytareli, Chrysoula, et al.
Publicado: (2023)

Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox
por: Vlachakis, Dimitrios, et al.
Publicado: (2013)

Antibody–Biopolymer Conjugates in Oncology: A Review
por: Chavda, Vivek P., et al.
Publicado: (2023)

Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Site-Specific Antibody Conjugation for ADC and Beyond
por: Zhou, Qun
Publicado: (2017)

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
por: Kondrashov, Aleksei, et al.
Publicado: (2023)

Emergency Surgery for Metastatic Melanoma
por: Mantas, Dimitrios, et al.
Publicado: (2014)

Site-selective lysine conjugation methods and applications towards antibody–drug conjugates
por: Haque, Muhammed, et al.
Publicado: (2021)

Application of Immuno-PET in Antibody–Drug Conjugate Development
por: Carmon, Kendra S., et al.
Publicado: (2018)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Unveiling Druggable Pockets by Site-Specific Protein Modification: Beyond Antibody-Drug Conjugates
por: Martínez, Dailén G., et al.
Publicado: (2020)

Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
por: Xiao, Tian, et al.
Publicado: (2023)

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
por: Liao, Michael Z., et al.
Publicado: (2021)

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review
por: Sakellariou, Stratigoula, et al.
Publicado: (2021)

Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications
por: Min, Jolene Wong Si, et al.
Publicado: (2022)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Computational Construction of Antibody–Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker
por: Filntisi, Arianna, et al.
Publicado: (2014)

Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins
por: Zhou, Qun
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rcnhvsui0kk339hea51t2abvsk